March 3, 2026

To Shareholders,

Company Name: Renascience Inc.
Representative: Toshio Miyata, Chairman and CEO
(Code: 4889 TSE Growth)
For inquiries, please contact Administration Dept.

Announcement of Agreement of the Tohoku University - University College London Matching Fund: Diabetes Treatment Support Program Medical Device

Our company's "Artificial intelligence (AI)-Based Diabetes Treatment Support Software for a Medical Device (SaMD)" was selected as a project for the "2026 Tohoku University - University College London Matching Fund" implemented by Tohoku University and University College London (UCL). We are pleased to announce that we have officially signed an agreement and will be implementing the project.

This matching fund was established based on an agreement between Tohoku University and UCL to promote and encourage joint research between the two universities. Nineteen applications were received, and a total of six were selected, including interdisciplinary collaborative research projects that combine multiple fields, such as those on resilient societies, spintronics, and the use of AI in the medical field (this project) (https://web.tohoku.ac.jp/ged/14494). Tohoku University and UCL have now concluded a Joint Research Agreement.

Joint Research Agreement

Project: Tohoku University-University College London Matching Fund
(https://web.tohoku.ac.jp/ged/14494)
Title: Smart Insulin Therapy: A UCL–Tohoku collaboration on reinforcement learning approaches for personalized diabetes management
Principal Investigators: Tohoku University, Prof. Toshio Miyata; UCL, Associate Prof. Kezhi Li
Research Period: April 1, 2026 to March 31, 2027

University College London (UCL) was founded in London in 1826 and is one of the UK's leading public research universities. To date, it has produced a total of 30 Nobel Prize winners and three Fields Medal winners.

To address challenges in the medical field, our company is collaborating with Tohoku University and several research and medical institutions to develop various medical solutions (software as a medical device: SaMD) utilizing artificial intelligence (AI), including maintenance hemodialysis medical support program medical devices and diabetes treatment support program medical devices (Nature Interview Article: https://www.nature.com/articles/d42473-023-00376-2). A multi-center collaborative verification clinical performance test for this diabetes treatment support program medical device was conducted as at six facilities in Japan, including Tohoku University Hospital, from August 2024. As a result of the trial, the primary endpoint, the "correct rate", which assessed the difference between diabetes specialists and the AI estimation, was approximately 85%, exceeding the initial target of 80%, enabling Proof-of-Concept (proof of effectiveness) for the SaMD to be obtained (disclosed on March 6, 2025).

This matching fund aims to realize even more advanced AI algorithms and personalized insulin therapy by combining the diabetes treatment SaMD developed by our company and Tohoku University with UCL's diabetes-related AI technology.

There is currently no impact on our financial results for the fiscal year ending March 2026, but we will make timely disclosures if any matters requiring disclosure arise in the future.